Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals (AMPH)
NASDAQ:AMPH
RESEARCH TOOLSreports
Total Valuation
Amphastar Pharmaceuticals has a market cap or net worth of $1.27B. The enterprise value is $1.31B.
Market Cap$1.27B
Enterprise Value$1.31B
Share Statistics
Amphastar Pharmaceuticals has 47,139,084 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding47,139,084
Owned by Insiders24.23%
Owned by Institutions15.19%
Financial Efficiency
Amphastar Pharmaceuticals’s return on equity (ROE) is 0.22 and return on invested capital (ROIC) is 12.28%.
Return on Equity (ROE)0.22
Return on Assets (ROA)0.10
Return on Invested Capital (ROIC)12.28%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee351.49K
Profits Per Employee78.66K
Employee Count2,028
Asset Turnover0.45
Inventory Turnover2.20
Valuation Ratios
The current PE Ratio of Amphastar Pharmaceuticals is 11.27. Amphastar Pharmaceuticals’s PEG ratio is 0.33.
PE Ratio11.27
PS Ratio0.00
PB Ratio2.57
Price to Fair Value2.46
Price to FCF20.88
Price to Operating Cash Flow15.25
PEG Ratio0.33
Income Statement
In the last 12 months, Amphastar Pharmaceuticals had revenue of 712.81M and earned 159.52M in profits. Earnings per share was 3.29.
Revenue712.81M
Gross Profit373.86M
Operating Income205.42M
Pretax Income189.76M
Net Income159.52M
EBITDA277.31M
Earnings Per Share (EPS)3.29
Cash Flow
In the last 12 months, operating cash flow was 193.17M and capital expenditures -42.95M, giving a free cash flow of 150.23M billion.
Operating Cash Flow193.17M
Free Cash Flow150.23M
Free Cash Flow per Share3.19
Dividends & Yields
Amphastar Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.66
52-Week Price Change-35.88%
50-Day Moving Average24.86
200-Day Moving Average36.61
Relative Strength Index (RSI)55.12
Average Volume (3m)521.56K
Important Dates
Amphastar Pharmaceuticals upcoming earnings date is Aug 11, 2025, TBA Not Confirmed.
Last Earnings DateMay 7, 2025
Next Earnings DateAug 11, 2025
Ex-Dividend Date―
Financial Position
Amphastar Pharmaceuticals as a current ratio of 3.07, with Debt / Equity ratio of 19.40%
Current Ratio3.07
Quick Ratio2.19
Debt to Market Cap0.33
Net Debt to EBITDA1.80
Interest Coverage Ratio6.77
Taxes
In the past 12 months, Amphastar Pharmaceuticals has paid 29.67M in taxes.
Income Tax29.67M
Effective Tax Rate0.16
Enterprise Valuation
Amphastar Pharmaceuticals EV to EBITDA ratio is 8.28, with an EV/FCF ratio of 13.33.
EV to Sales3.22
EV to EBITDA8.28
EV to Free Cash Flow13.33
EV to Operating Cash Flow10.77
Balance Sheet
Amphastar Pharmaceuticals has $236.88M in cash and marketable securities with $652.53M in debt, giving a net cash position of $415.65M billion.
Cash & Marketable Securities$236.88M
Total Debt$652.53M
Net Cash$415.65M
Net Cash Per Share$8.82
Tangible Book Value Per Share$2.92
Margins
Gross margin is 49.87%, with operating margin of 28.82%, and net profit margin of 22.38%.
Gross Margin49.87%
Operating Margin28.82%
Pretax Margin26.62%
Net Profit Margin22.38%
EBITDA Margin38.90%
EBIT Margin30.88%
Analyst Forecast
The average price target for Amphastar Pharmaceuticals is $31.50, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$31.50
Price Target Upside20.92% Upside
Analyst ConsensusHold
Analyst Count5
Revenue Growth Forecast8.05%
EPS Growth Forecast-8.46%